睿智医药9月24日获融资买入1489.34万元，融资余额2.34亿元

Core Viewpoint - The company, Ruizhi Pharmaceutical, has shown a mixed performance in terms of financing activities and stockholder metrics, with notable growth in revenue and net profit for the first half of 2025 [1][2]. Financing Activities - On September 24, 2023, Ruizhi Pharmaceutical's stock price increased by 0.33%, with a trading volume of 178 million yuan. The financing buy-in amount was 14.89 million yuan, while the financing repayment was 17.60 million yuan, resulting in a net financing outflow of 2.70 million yuan [1]. - As of September 24, 2023, the total financing and securities lending balance for Ruizhi Pharmaceutical was 234 million yuan, which accounts for 3.91% of its market capitalization. The financing balance is above the 80th percentile of the past year, indicating a high level [1]. - In terms of securities lending, there were no shares sold or repaid on September 24, 2023, with a remaining securities lending balance of 11.39 million yuan, which is above the 60th percentile of the past year, also indicating a high level [1]. Shareholder Metrics - As of September 20, 2023, the number of shareholders for Ruizhi Pharmaceutical was 44,700, a decrease of 5.99% from the previous period. The average number of circulating shares per shareholder increased by 6.37% to 10,626 shares [2]. - The company has cumulatively distributed 180 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 534 million yuan, representing a year-on-year growth of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, showing a significant year-on-year increase of 140.35% [2].